Chinese regulators have approved Novartis’ Mayzent to treat relapsing
multiple sclerosis in adults, the Swiss drug maker said in a statement
on Saturday.
Other drugs approved by China’s National Medical Products
Administration to treat MS include Novartis’ Gilenya, Bayer’s Betaferon
and Sanofi’s Aubagio. China has an estimated 30,000 patients with MS.
https://www.reuters.com/article/us-novartis-china-multiple-sclerosis/china-approves-novartis-multiple-sclerosis-treatment-mayzent-idUSKBN22L0C6
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.